Published in J Clin Endocrinol Metab on March 01, 2003
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid (2015) 1.42
The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 1.02
Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid (2012) 1.00
The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev (2011) 0.98
Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation? Ann Surg Oncol (2012) 0.95
Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma? Clin Exp Otorhinolaryngol (2008) 0.93
Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer. Thyroid (2013) 0.88
Treatment and follow-up of low-risk patients with thyroid cancer. Nat Rev Endocrinol (2011) 0.85
Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2005) 0.83
Favourable course of disease after incomplete remission on (131)I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up. Eur J Nucl Med Mol Imaging (2010) 0.80
Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin. Korean J Intern Med (2010) 0.79
Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2015) 0.76
Clinical diagnostics and therapy monitoring in the congenital disorders of glycosylation. Glycoconj J (2016) 0.76
Which thyroid cancer patients need periodic stimulation tests? Eur J Nucl Med Mol Imaging (2006) 0.76
Evaluation of Thyroid Bed Nodules on Ultrasonography after Total Thyroidectomy: Risk for Loco-Regional Recurrence of Thyroid Cancer. Eur Thyroid J (2015) 0.75
The stratification of patient risk depending on the size and ratio of metastatic lymph nodes in papillary thyroid carcinoma. World J Surg Oncol (2017) 0.75
Clinical use of PET/CT in thyroid cancer diagnosis and management. Biomed Imaging Interv J (2006) 0.75
Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management. Onco Targets Ther (2009) 0.75
Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value. Eur J Nucl Med Mol Imaging (2004) 0.75
Controversies in the Management of Low-Risk Differentiated Thyroid Cancer. Endocr Rev (2017) 0.75
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab (2006) 5.78
Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab (1986) 2.70
Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer (1998) 2.57
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
Second primary malignancies in thyroid cancer patients. Br J Cancer (2003) 2.10
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) (1998) 1.99
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab (2005) 1.98
Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab (2000) 1.96
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab (1999) 1.92
High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene (1997) 1.91
Analysis of local-regional relapses in patients with early breast cancers treated by excision and radiotherapy: experience of the Institut Gustave-Roussy. Int J Radiat Oncol Biol Phys (1985) 1.74
Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet (2001) 1.68
Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab (1999) 1.67
Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer (1985) 1.66
Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol (2004) 1.52
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer (2004) 1.52
Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol (1999) 1.51
Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med (1996) 1.49
ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene (2011) 1.45
Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res (2000) 1.43
Presence of mutations in all three ras genes in human thyroid tumors. Oncogene (1990) 1.42
Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) (2010) 1.41
Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res (1993) 1.41
gsp mutations in human thyroid tumours. Oncogene (1991) 1.37
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer (2011) 1.36
Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer (1989) 1.35
RET mutations in exons 13 and 14 of FMTC patients. Oncogene (1995) 1.35
Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res (2001) 1.30
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer (2001) 1.30
External radiotherapy in thyroid cancers. Cancer (1985) 1.28
Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab (1997) 1.25
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer (1998) 1.23
The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer (2004) 1.22
Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer (1988) 1.20
Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab (2011) 1.20
Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer (2001) 1.19
Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab (1998) 1.18
Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol (2010) 1.18
Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am J Hum Genet (1997) 1.16
Expression of pendrin and the Pendred syndrome (PDS) gene in human thyroid tissues. J Clin Endocrinol Metab (2000) 1.15
Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab (2012) 1.13
Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med (2000) 1.13
Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab (1997) 1.12
Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene (1988) 1.12
Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab (2005) 1.11
Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. J Clin Endocrinol Metab (2010) 1.11
Expression of Na+/I- symporter and Pendred syndrome genes in trophoblast cells. J Clin Endocrinol Metab (2000) 1.10
Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab (1998) 1.08
Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest (1992) 1.07
Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium. J Clin Endocrinol Metab (1999) 1.07
Na(+)/I(-) symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. Eur J Endocrinol (2001) 1.07
Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol (2007) 1.06
Expression of reduced nicotinamide adenine dinucleotide phosphate oxidase (ThoX, LNOX, Duox) genes and proteins in human thyroid tissues. J Clin Endocrinol Metab (2001) 1.06
Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab (1987) 1.05
Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori (1990) 1.04
Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab (2009) 1.04
Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer (2011) 1.04
Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol (2001) 1.03
Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC). Br J Cancer (2000) 1.02
Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors. Int J Radiat Oncol Biol Phys (1997) 1.02
Arterioureteral fistula after extended resection of pelvic tumors: report of three cases and review of the literature. Ann Vasc Surg (1992) 1.02
Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med (1996) 1.02
Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst (1993) 1.01
Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: incidence, clinical course, and outcome. J Clin Oncol (1989) 1.01
Conservative management of breast cancer. Br J Surg (1986) 1.00
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol (2013) 1.00
Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab (1998) 0.99
Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab (1998) 0.98
Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol (2009) 0.98
Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest (2004) 0.98
Notch signaling is involved in expression of thyrocyte differentiation markers and is down-regulated in thyroid tumors. J Clin Endocrinol Metab (2008) 0.97
Pulmonary artery tumour-embolism diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. Eur Respir J (2011) 0.96
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab (2009) 0.96
The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab (1998) 0.96
Oncogenic potential of guanine nucleotide stimulatory factor alpha subunit in thyroid glands of transgenic mice. Proc Natl Acad Sci U S A (1994) 0.95
Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol (2009) 0.95
Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B. Eur J Endocrinol (2009) 0.94
Pheochromocytoma and paraganglioma in children: a report of 24 cases of the French Society of Pediatric Oncology. Pediatr Hematol Oncol (1997) 0.93
The etiology of bacterial pneumonia and meningitis in Vietnam. Pediatr Infect Dis J (1998) 0.93